PRICE T ROWE ASSOCIATES INC /MD/ - SAGE THERAPEUTICS INC ownership

SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 218 filers reported holding SAGE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of SAGE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$11,984
-76.4%
582,272
-46.1%
0.00%
-71.4%
Q2 2023$50,789
-36.6%
1,080,153
-43.4%
0.01%
-41.7%
Q1 2023$80,077
+10.7%
1,908,391
+0.6%
0.01%0.0%
Q4 2022$72,364
-99.9%
1,897,322
-11.4%
0.01%
-14.3%
Q3 2022$83,819,000
+24.9%
2,140,411
+3.0%
0.01%
+75.0%
Q2 2022$67,104,000
-6.1%
2,077,534
-3.8%
0.01%
+14.3%
Q1 2022$71,446,000
+18.6%
2,158,504
+52.4%
0.01%
+40.0%
Q4 2021$60,259,000
-3.3%
1,416,522
+0.7%
0.01%
-16.7%
Q3 2021$62,339,000
-30.2%
1,406,889
-10.5%
0.01%
-25.0%
Q2 2021$89,280,000
-50.4%
1,571,553
-34.7%
0.01%
-55.6%
Q1 2021$180,152,000
-11.7%
2,406,847
+2.1%
0.02%
-14.3%
Q4 2020$203,934,000
+30.4%
2,357,342
-7.9%
0.02%
+16.7%
Q3 2020$156,408,000
+33.4%
2,559,034
-9.2%
0.02%
+20.0%
Q2 2020$117,216,000
+37.7%
2,819,052
-4.9%
0.02%
+15.4%
Q1 2020$85,135,000
-79.1%
2,964,308
-47.5%
0.01%
-75.5%
Q4 2019$407,815,000
-61.1%
5,649,188
-24.3%
0.05%
-64.2%
Q3 2019$1,047,048,000
-27.6%
7,463,451
-5.6%
0.15%
-27.1%
Q2 2019$1,447,195,000
+9.4%
7,904,284
-4.9%
0.20%
+4.6%
Q1 2019$1,322,296,000
+72.1%
8,313,715
+3.7%
0.19%
+49.2%
Q4 2018$768,275,000
-29.8%
8,020,411
+3.5%
0.13%
-18.8%
Q3 2018$1,095,060,000
-8.3%
7,752,634
+1.6%
0.16%
-12.6%
Q2 2018$1,194,704,000
+3.6%
7,632,429
+6.7%
0.18%0.0%
Q1 2018$1,152,637,000
+10.9%
7,156,124
+13.4%
0.18%
+8.3%
Q4 2017$1,039,537,000
+257.5%
6,311,317
+35.2%
0.17%
+238.0%
Q3 2017$290,776,000
+3.2%
4,667,359
+31.9%
0.05%
-2.0%
Q2 2017$281,836,000
+19.0%
3,538,873
+6.2%
0.05%
+15.9%
Q1 2017$236,890,000
+81.3%
3,333,190
+30.3%
0.04%
+69.2%
Q4 2016$130,628,000
+102.4%
2,558,333
+82.5%
0.03%
+100.0%
Q3 2016$64,547,000
+354.8%
1,401,678
+197.6%
0.01%
+333.3%
Q2 2016$14,193,000
+16.0%
471,070
+23.5%
0.00%0.0%
Q1 2016$12,232,000
-45.0%
381,5250.0%0.00%
-40.0%
Q4 2015$22,243,000
-28.2%
381,525
-47.8%
0.01%
-28.6%
Q3 2015$30,958,000
+1.5%
731,510
+75.0%
0.01%
+16.7%
Q2 2015$30,509,000
+575.7%
417,927
+365.0%
0.01%
+500.0%
Q1 2015$4,515,00089,8780.00%
Other shareholders
SAGE THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
Integral Health Asset Management, LLC 409,000$17,399,0004.82%
Palo Alto Investors LP 781,730$33,255,0002.12%
DAFNA Capital Management LLC 180,306$7,670,0001.93%
Boxer Capital, LLC 1,094,000$46,539,0001.81%
Deep Track Capital, LP 500,000$21,270,0001.50%
Bellevue Group AG 3,228,004$137,319,0001.42%
EcoR1 Capital, LLC 940,636$40,015,0001.28%
Deep Track Capital, LP 400,000$17,016,0001.20%
Artal Group S.A. 1,000,000$42,540,0001.15%
SECTOR GAMMA AS 98,904$4,207,0000.99%
View complete list of SAGE THERAPEUTICS INC shareholders